Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Instituto Oncológico Dr Rosell
- Target Recruit Count
- 32
- Registration Number
- NCT04772235
- Locations
- 🇪🇸
Hospital Regional Universitario de Málaga, Málaga, Andalucia, Spain
🇪🇸Hospital Son Espases, Palma, Baleares, Spain
🇪🇸Hospital Universitario Gregorio Marañón, Madrid, Spain
Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge
Phase 1
- Conditions
- Covid19Pulmonary Fibrosis
- Interventions
- Biological: IN01 vaccine
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Instituto Oncológico Dr Rosell
- Target Recruit Count
- 40
- Registration Number
- NCT04537130
- Locations
- 🇪🇸
Hospital El Pilar, Barcelona, Spain
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Instituto Oncológico Dr Rosell
- Target Recruit Count
- 20
- Registration Number
- NCT04487756
- Locations
- 🇪🇸
ICO Badalona, Badalona, Barcelona, Spain
🇪🇸Hospital Clínic Barcelona, Barcelona, Spain
🇪🇸Quirón Dexeus, Barcelona, Spain
E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Instituto Oncológico Dr Rosell
- Target Recruit Count
- 23
- Registration Number
- NCT03623750
- Locations
- 🇪🇸
Instituto Oncológico Dr. Rosell, Barcelona, Spain
🇪🇸Hospital Clínic Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario Regional de Málaga, Málaga, Spain
© Copyright 2025. All Rights Reserved by MedPath